BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng, J Liu… - Advanced …, 2023 - Wiley Online Library
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
[HTML][HTML] BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng, J Liu… - Advanced …, 2023 - ncbi.nlm.nih.gov
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng… - Advanced Science …, 2023 - europepmc.org
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng… - Advanced …, 2023 - search.proquest.com
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu… - Advanced science …, 2023 - pubmed.ncbi.nlm.nih.gov
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …